de5a4588-05ec-461f-9235-90611b01f4b6
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.700
- MYC_TARGETS_V1+0.700
- MYC_TARGETS_V2+0.700
- G2M_CHECKPOINT+0.600
- DNA_REPAIR+0.400
- MITOTIC_SPINDLE+0.400
- MTORC1_SIGNALING+0.400
- OXIDATIVE_PHOSPHORYLATION+0.300
- PI3K_AKT_MTOR_SIGNALING+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.300
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.400
- ANGIOGENESIS-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- ESTROGEN_RESPONSE_EARLY-0.300
- KRAS_SIGNALING_DN-0.300
- MYOGENESIS-0.300
- BILE_ACID_METABOLISM-0.200
- COAGULATION-0.200
- ESTROGEN_RESPONSE_LATE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0D600773-1B42-4F04-BCEA-39F658DF63F1 | — | — | 0.850 |
| 2 | BS_1EBQ3T20 | high-grade glioma | — | 0.831 |
| 3 | TCGA-A8-A07O-01A-11R-A00Z-07 | — | E | 0.828 |
| 4 | TCGA-BH-A18T-01A-11R-A12D-07 | — | E | 0.827 |
| 5 | SRR934937 | — | — | 0.827 |
| 6 | TCGA-AN-A0AT-01A-11R-A034-07 | — | E | 0.822 |
| 7 | c58c72c3-3152-461a-b55a-9bcccc0b71f4 | — | — | 0.821 |
| 8 | SRR8518152 | — | E | 0.819 |
| 9 | d9eacc36-0ae3-41bd-aef6-503f91cb25aa | — | — | 0.815 |
| 10 | MNG922 | — | — | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.700 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.700 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.700 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.600 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |